Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2013 May 21;8(4):988–997. doi: 10.1007/s11481-013-9472-6

Fig. 2.

Fig. 2

Mean peak ASR amplitude during 0 msec ISI control trials across the PPI test session at each age (±95% CI). Trials are numbered 1 through 12 for simplicity, although they were presented across the 72-trial session in a Latin square. The ASR of the HIV-1 Tg group decreased across 0 msec ISI trials within each test session, with a single phase decay function accounting for over 90% of the variance in each session. In contrast, the ASR of the control group did not significantly change across 0 msec ISI trials during any test session.